TP53 mutations were more frequent in tumours with CTR ranging from 0.5 to 1 (44.3%, 13/30) than in those with CTR ranging from 0.25 to 0.5 (14.3%, 2/14) and from 0 to 0.25 (8.2%, 4/49) (P=0.001) (Table 2). Here, TP53 is linked to neoplasm.